Various nano-formulations containing SBECD have been studied in order to utilize the inclusion complex forming (solubilizing, stabilizing) ability of this CD derivative in synergy with the benefits of the nanosized particles/droplets (1). Some examples are listed below:
Nanoparticles formed by chitosan and SBE-β-CD were thoroughly studied for various drugs, such as econazole nitrate and hydrocortisone (2,3). They were also used to formulate slow-release tablet of famotidine (4). Zhang et al. developed naringenin-loaded SBE-β- CD-chitosan nanoparticles for ocular administration (5). The results of in vivo studies in rabbits showed that naringenin bioavailability was significantly enhanced in aqueous humor in comparison to naringenin suspension. Chitosan/SBECD surface-adsorbed naringenin-loaded nanocapsules were found to enhance bacterial quorum quenching and showed anti-biofilm activities against Pseudomonas aeruginosa (6).
Nanoemulsions (nanodroplets) have similar advantages. Li et al. (7) found that the surfactant Kolliphor® HS 15 (HS 15) and SBECD had significant synergistic effects on solubilizing voriconazole, and a novel voriconazole complex delivery system (VRC-CD/HS 15) was established which had better physicochemical properties and similar antifungal effect compared to the marketed SBECD-enabled formulation of voriconazole. Nanoemulsion stabilized by various surfactants (Tween 80, poloxamer 407 and polyethylene glycol 400) were prepared to form carnosic acid/SBECD nanoparticles (>100 nm) to improve the solubility, circulation stability and brain bioavailability of carnosic acid (8).
- Das O, Ghate VM, Lewis SA. (2019) Utility of Sulfobutyl Ether beta-Cyclodextrin Inclusion Complexes in Drug Delivery: A Review. Indian J Pharm Sci 81, 589-600. https://doi.org/10.36468/pharmaceutical-sciences.549
- Mahmoud AA, El-Feky GS, Kamel R, Awad GE. (2011) Chitosan/sulfobutylether-β-cyclodextrin nanoparticles as a potential approach for ocular drug delivery. Int J Pharm 413, 229-236. https://doi.org/10.1016/j.ijpharm.2011.04.031
- Fulop Z, Saokham P, Loftsson T. (2014) Sulfobutylether-beta-cyclodextrin/chitosan nano- and microparticles and their physicochemical characteristics. Int J Pharm 472, 282-287. https://doi.org/10.1016/j.ijpharm.2014.06.039
- Anraku M, Hiraga A, Iohara D, Pipkin JD, Uekama K, Hirayama F. (2015) Slow-release of famotidine from tablets consisting of chitosan/sulfobutyl ether β-cyclodextrin composites. Int J Pharm 487, 142-147. https://doi.org/10.1016/j.ijpharm.2015.04.022
- Zhang P, Liu X, Hu W, Bai Y, Zhang L. (2016) Preparation and evaluation of naringenin loaded sulfobutyl ether beta cyclodextrin chitosan nanoparticles for ocular delivery. Carbohydr Polym 149, 224-230. https://doi.org/10.1016/j.carbpol.2016.04.115
- Nguyen HT, Hensel A, Goycoolea FM. (2021) Chitosan/cyclodextrin surface-adsorbed naringenin-loaded nanocapsules enhance bacterial quorum quenching and anti-biofilm activities. Colloids and Surfaces B: Biointerfaces 112281. https://doi.org/10.1016/j.colsurfb.2021.112281.
- Li Y, Zhu C , Wu H , Pan H, Liu H. (2020) Kolliphor® HS 15-cyclodextrin Complex for the Delivery of Voriconazole: Preparation, Characterization, and Antifungal Activity, Current Drug Metabolism 21(5), 379-389. https://dx.doi.org/10.2174/1389200221666200520085915
- Wang Y-B, Xiang L, Bing Y et al. (2022) Inhibition of the CEBPβ-NFκB interaction by nanocarrier-packaged Carnosic acid ameliorates glia-mediated neuroinflammation and improves cognitive function in an Alzheimer’s disease model. Cell Death Dis 13, 318. https://doi.org/10.1038/s41419-022-04765-1